Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
18 hedge funds and large institutions have $699K invested in Statera Biopharma, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 5 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
9% less capital invested
Capital invested by funds: $764K → $699K (-$65K)
18% less funds holding
Funds holding: 22 → 18 (-4)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
+$407K |
| 2 |
Morgan Stanley
New York
|
+$43.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$17.3K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$17.2K |
| 5 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$5.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$96.3K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$65K |
| 3 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$46.5K |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$27K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$1K |
STAB Hedge Fund Activity: Q2 2015 in Review
18 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q2 2015, worth a combined $699K — down 8.5% from $764K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of STAB and 1 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 6 added.
The largest buyer was Pine River Capital Management, adding an estimated $407K. The largest seller was Renaissance Technologies, cutting an estimated $96.3K.
- 18 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q2 2015, down from 22 in Q1 2015.
- Funds reported $699K of Statera Biopharma, Inc. Common Stock stock for Q2 2015, down 8.5% quarter-over-quarter.
- 1 fund opened new Statera Biopharma, Inc. Common Stock positions in Q2 2015 and 5 closed out, a net change of -4 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q2 2015 was Pine River Capital Management, an estimated $407K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q2 2015 was Renaissance Technologies, an estimated $96.3K sold.
Based on aggregated 13F filings for Q2 2015.